A Phase 2 interventional study of Pegylated Interferon (Peginterferon) Alfa-2a and Nucleos(t)ide Analogues (NA) in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 27 sites in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-02-20.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 38th largest by enrollment, is one of 2 that started in 2013, is one of 5 in phase 2, and was the 32nd registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:
IntegerBio · Sites in Hong Kong, Moldova, New Zealand and 1 more country
Ages 18–70 · Healthy volunteers
By country, each count listing its studies:
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 12 · Phase 4 29
First in 2002; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 114 across the 59 interventional studies. Of the 39 that completed or were terminated, 17 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 59 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
46 studies in Hepatitis B, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 45 finished, 25 (56%) have results posted.
Among the 46 studies in Hepatitis B, Chronic by Hoffmann-La Roche, this one is the 18th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2013, is one of 4 in phase 2, and was the 26th registered.
Hoffmann-La Roche’s Hepatitis B, Chronic studies by the year they started, since 2002.
1 of the studies testing peginterferon alfa-2a in Hepatitis B, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07389044IntegerBioA Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 46 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, single-arm, multicenter study will evaluate the efficacy and safety of adding Pegasys (peginterferon alfa-2a) to nucleos(t)ide analogue (NAs) treatment in participants with HBeAg-negative chronic hepatitis B genotype D showing stable HBV DNA suppression. After a 12-week Lead-in period on treatment with NA, participants with a HBsAg decline \<0.5 log10 IU/ml will enter the Add-on period to receive Pegasys 180 mcg subcutaneously weekly for 48 weeks in addition to their current NA treatment. Follow-up will be a further 48 weeks, during which the participants will continue their NA treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receiving nucleos(t)ide analogues (NA) therapy with Hepatitis B surface Antigen (HBsAg) decline less than \<0.5 log 10 international unit/milliliter (IU/ml) at baseline received peginterferon alfa-2a 180 microgram (mcg), subcutaneously (SC) once weekly for 48 weeks along with their NA therapy.
Drug: Pegylated Interferon (Peginterferon) Alfa-2a · Drug: Nucleos(t)ide Analogues (NA)
Peginterferon alfa-2a 180 mcg, subcutaneously (SC) once weekly for 48 weeks.
Also known as: Pegasys
Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.
Efficacy: Percent Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Titer at End of the Combination Treatment (Week 48)
Time frame: Baseline up to Week 48
Efficacy: Percentage of Participants With Serum Hepatitis B Surface Antigen (HBsAg) Decrease >/= 50% From Baseline at End of the Combination Treatment (Week 48)
Participants who stopped pegylated interferon (PEG-IFN) treatment during the add-on phase due to serum HBsAg loss and HBsAg seroconversion were considered as responders.
Time frame: Baseline and Week 48
Efficacy: Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Titer at Week 24, 72 and 96
Change is calculated by HBsAg titer at baseline - HBsAg titer at week of assessments.
Time frame: Baseline, Week 24, 72 and 96
Efficacy: Percentage of Participants With HBsAg Decrease >/=1 log10 IU/ml From Baseline to Week 48
Time frame: Baseline, Week 48
Efficacy: Number of Participants With Serum HBsAg Loss at Week 12 That Persisted up to Week 96
HBsAg loss is defined as HBsAg less than or equal to (\</=) 0.05 IU/ml.
Time frame: Week 12 up to Week 96
Efficacy: HBsAg Levels According to Interleukin 28B (IL28B) Genotypes
Time frame: Baseline and Week 48
Efficacy: HBsAg Levels According to Interferon-Inducible Protein 10 (IP-10) Serum Levels
Time frame: Baseline and Week 48
Safety: Percentage of Participants With Adverse Events (AE)
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Baseline up to Week 48
| Milestone | Pegylated Interferon (Peginterferon) Alfa-2a |
|---|---|
| Started | 76 |
| Treated | 70 |
| Completed | 64 |
| Not completed | 12 |
| Withdrew: Participant withdrew consent | 4 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Started but not treated | 6 |
| percent change | Pegylated Interferon (Peginterferon) Alfa-2a |
|---|---|
| Efficacy: Percent Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Titer at End of the Combination Treatment (Week 48) | 59.13 ± 32.14 |
Participants who stopped pegylated interferon (PEG-IFN) treatment during the add-on phase due to serum HBsAg loss and HBsAg seroconversion were considered as responders.
| percentage of participants | Pegylated Interferon (Peginterferon) Alfa-2a |
|---|---|
| Efficacy: Percentage of Participants With Serum Hepatitis B Surface Antigen (HBsAg) Decrease >/= 50% From Baseline at End of the Combination Treatment (Week 48) | 67.44 |
Change is calculated by HBsAg titer at baseline - HBsAg titer at week of assessments.
| international units per millilitre | Pegylated Interferon (Peginterferon) Alfa-2a |
|---|---|
| Baseline (n= 56) | 0 ± 0 |
| Change at Week 24 (n= 56) | -546.32 ± 1215.20 |
| Change at Week 72 (n= 55) | -815.69 ± 1394.89 |
| Change at Week 96 (n= 55) | -728.16 ± 1418.60 |
| percentage of participants | Pegylated Interferon (Peginterferon) Alfa-2a |
|---|---|
| Efficacy: Percentage of Participants With HBsAg Decrease >/=1 log10 IU/ml From Baseline to Week 48 | 13.95 |
HBsAg loss is defined as HBsAg less than or equal to (\</=) 0.05 IU/ml.
| participants | Pegylated Interferon (Peginterferon) Alfa-2a |
|---|---|
| Efficacy: Number of Participants With Serum HBsAg Loss at Week 12 That Persisted up to Week 96 | 1 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| percentage of participants | Pegylated Interferon (Peginterferon) Alfa-2a |
|---|---|
| Safety: Percentage of Participants With Adverse Events (AE) | 92.75 |
Collected over Baseline up to Week 48. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pegylated Interferon (Peginterferon) Alfa-2a | — | 5/69 (7.2%) | 56/69 (81.2%) |
| Event | Pegylated Interferon (Peginterferon) Alfa-2a |
|---|---|
| Papillary thyroid cancerEndocrine disorders | 1/69 |
| PyrexiaGeneral disorders | 1/69 |
| Rib fractureInjury, poisoning and procedural complications | 1/69 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/69 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/69 |
| HemoptysisRespiratory, thoracic and mediastinal disorders | 1/69 |
| Event | Pegylated Interferon (Peginterferon) Alfa-2a |
|---|---|
| AstheniaGeneral disorders | 27/69 |
| HeadacheNervous system disorders | 19/69 |
| PyrexiaGeneral disorders | 18/69 |
| MyalgiaMusculoskeletal and connective tissue disorders | 15/69 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 11/69 |
| ThrombocytopeniaBlood and lymphatic system disorders | 8/69 |
| InsomniaPsychiatric disorders | 7/69 |
| Decreased appetiteMetabolism and nutrition disorders | 6/69 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/69 |
| Back painMusculoskeletal and connective tissue disorders | 6/69 |
Lead-in participants included all participants enrolled in lead-in period.
| Age, Continuous(years) | Pegylated Interferon (Peginterferon) Alfa-2a |
|---|---|
| Mean | 49.82 ± 8.46 |
| Gender(Participants) | Pegylated Interferon (Peginterferon) Alfa-2a |
|---|---|
| Female | 13 |
| Male | 63 |
The record gives a start of Jan 2013, a primary completion of Sep 2013 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2a